secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K/A
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001104659-25-097919
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment
--------------------------------------------------------------------------------

- Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
- Concurrent investment: DEFJ buys 223.7337 Series B Preferred at $111,740/share, raising ~$25M ($20M cash + $5M promissory note at 4% due Jan 2026).
- Up to $95M in contingent milestone payments to DEFJ upon achievement of certain milestones.
- Each common shareholder receives one CVR, entitling holder to 50% of net proceeds from upfront/milestone payments over 7 years.
- Stockholder meeting needed to approve conversion of Series A Preferred and change of control under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925097919/0001104659-25-097919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925097919/tm2528282d3_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer